CRP and chronic obstructive pulmonary disease: Despite these results, the study showed no changes in inflammatory biomarkers (C-reactive protein and fecal calprotectin), and the development for the CD indication was halted due to this discrepancy.AZD9056 was further assessed in a 4-week study for chronic obstructive pulmonary disease (COPD), where patients received 400 mg orally once daily.